Due-diligence datasheet · Regulatory status
PT-141 is FDA-approved for exactly one indication — here is precisely what that line covers, and what it does not.
Bremelanotide (NDA 210557, approved June 21, 2019) treats one diagnosis in one population. Every approved fact, every off-label boundary, every contraindication — logged to its source like a spec sheet.
Start here — the short version
PT-141 (also called bremelanotide) is a small lab-made peptide — a chain of amino acids built into a ring. It works in the brain, not in blood vessels. It switches on a brain receptor called MC4R (a docking site that helps control sexual desire), and that nudge raises desire and arousal [1].
Here is the line a careful reader wants drawn. The U.S. Food and Drug Administration (FDA, the agency that approves medicines) approved bremelanotide in June 2019 for one problem in one group: low sexual desire that causes real distress in women who have not yet gone through menopause [3][7]. That is the whole approval. It was not approved for men, for women past menopause, for erection problems, or for "performance" [10]. Those uses are off-label — meaning a doctor may prescribe outside the approved label, but the FDA has not signed off on them.
A separate thing sold online as "PT-141 research chemical" sits outside this approval entirely — no agency checks its identity, strength, or purity. What people actually report, including the downsides, is on the effects page.
What the FDA actually approved
The approval is narrow and specific, and that specificity is the whole point of this site. Bremelanotide was approved on June 21, 2019 under NDA 210557 for acquired, generalized hypoactive sexual desire disorder (HSDD) — persistently low sexual desire that causes marked distress — in premenopausal women [7][10]. The approved dose is 1.75 mg injected under the skin, used as needed, no more than one dose in 24 hours and no more than eight doses per month [7].
The evidence behind that approval was substantial. Two identical Phase 3 trials (RECONNECT, 1,267 premenopausal women with HSDD) met both of their main goals: bremelanotide improved sexual desire and lowered the distress tied to low desire versus placebo over 24 weeks [3].
What the approval did not cover matters just as much. Despite earlier studies in men with erectile dysfunction, bremelanotide is not approved for men, postmenopausal women, erectile dysfunction, or sexual "enhancement" [1][10]. The full is PT-141 fda-approved breakdown lays out every approved and off-label line as a spec table.
How it works — brain, not blood flow
PT-141 is a synthetic version of alpha-MSH (a natural brain-signaling peptide). It activates melanocortin receptors — chiefly MC4R (a receptor concentrated in the hypothalamus, the brain's control hub for drives like hunger and sex) [1].
That central action is the key contrast a careful reader should hold onto. PDE-5 inhibitors — the familiar erection-pill class — work peripherally, on the smooth muscle of blood vessels. PT-141 does not. It works in the brain's circuitry of sexual motivation, engaging dopamine pathways linked to desire [1][5]. A neuroimaging study in women with HSDD showed MC4R activation changed how the brain processed erotic cues and raised desire for up to 24 hours [5].
It is not a testosterone booster and does not work through the hormone axis that controls testosterone. That is a common misconception worth correcting up front. The full mechanism, with citations, is on the PT-141 research page.
What to watch for
An honest datasheet leads with its caveats. Nausea is common — about 40% of long-term users reported it, and it is a leading reason people stop [4]. Flushing and headache are the next most frequent [3][4]. Bremelanotide also causes transient increases in blood pressure, so the label warns against use in uncontrolled high blood pressure or known cardiovascular disease [7]. Repeated frequent dosing can darken skin, gums, and other tissue (hyperpigmentation), tied to a separate melanocortin receptor [11].
There is also a measured debate over how large the real-world benefit is: an effect-size analysis found HSDD drugs including bremelanotide produced gains modest relative to placebo [14]. And the material sold as "PT-141 research chemical" carries a risk the approved drug does not — no oversight of what is actually in the vial [10]. The full account, clearly labeled, is on PT-141 effects.